Cargando…

JAK3 Mutations and Mitochondrial Apoptosis Resistance in T-Cell Acute Lymphoblastic Leukemia

Resistance to mitochondrial apoptosis predicts inferior treatment outcomes in patients with diverse tumor types, including T-cell acute lymphoblastic leukemia (T-ALL). However, the genetic basis for variability in this mitochondrial apoptotic phenotype is poorly understood, preventing its rational t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bodaar, Kimberly, Yamagata, Natsuko, Barthe, Anais, Landrigan, Jack, Chonghaile, Triona Ni, Burns, Melissa, Stevenson, Kristen E., Devidas, Meenakshi, Loh, Mignon L., Hunger, Stephen P., Wood, Brent, Silverman, Lewis B., Teachey, David T., Meijerink, Jules P., Letai, Anthony, Gutierrez, Alejandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177679/ https://www.ncbi.nlm.nih.gov/pubmed/35411095 http://dx.doi.org/10.1038/s41375-022-01558-5

Ejemplares similares

PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia
por: Ariës, Ingrid M., et al.
Publicado: (2018)

Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia
por: Burns, Melissa A., et al.
Publicado: (2018)

Identification of TCF3 germline variants in pediatric B-cell acute lymphoblastic leukemia
por: Escherich, Carolin, et al.
Publicado: (2022)

P329: HIGH IMMUNOPROTEASOME ACTIVITY AS NOVEL INDICATOR FOR SENSITIVITY TO BORTEZOMIB-CONTAINING CHEMOTHERAPY IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM CHILDREN’S ONCOLOGY GROUP TRIAL AALL1231
por: Roeten, Margot, et al.
Publicado: (2023)

Prognostic impact of pretreatment immunoglobulin clonal composition in pediatric B-lymphoblastic leukemia
por: Fries, Carol, et al.
Publicado: (2022)

Epigenetic silencing of SOCS5 potentiates JAK‐STAT signaling and progression of T‐cell acute lymphoblastic leukemia
por: Sharma, Nitesh D., et al.
Publicado: (2019)

S107: IDENTIFICATION AND CHARACTERIZATION OF GERMLINE NBN VARIANTS RELATED TO B-ALL PREDISPOSITION
por: Escherich, Carolin, et al.
Publicado: (2023)

Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia
por: Yang, Wenjian, et al.
Publicado: (2022)

Germline Genetic NBN Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children
por: Escherich, Carolin, et al.
Publicado: (2023)

BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics
por: Touzeau, Cyrille, et al.
Publicado: (2015)

Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL
por: Kang, Huining, et al.
Publicado: (2018)

Long-term Results Of the Pediatric Oncology Group Studies For Childhood Acute Lymphoblastic Leukemia 1984-2001: A Report From The Children’s Oncology Group
por: Salzer, Wanda L., et al.
Publicado: (2009)

Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia
por: Pouliot, Gayle P., et al.
Publicado: (2019)

Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG
por: Burke, Michael J., et al.
Publicado: (2019)

Editorial: Cell Death and Targeted Cancer Therapies
por: Bagci-Onder, Tugba, et al.
Publicado: (2022)

Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia
por: Karol, Seth E., et al.
Publicado: (2017)

Long Term Results of the Children’s Cancer Group Studies for Childhood Acute Lymphoblastic Leukemia 1983–2002: a Children’s Oncology Group Report
por: Gaynon, Paul S., et al.
Publicado: (2009)

Identification and targeting of treatment resistant progenitor populations in T-cell Acute Lymphoblastic Leukemia
por: Tan, Kai, et al.
Publicado: (2023)

Outstanding outcomes in infants with KMT2Agermline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial
por: Guest, Erin M., et al.
Publicado: (2022)

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
por: Galimberti, Stefania, et al.
Publicado: (2018)

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
por: Degryse, Sandrine, et al.
Publicado: (2015)

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia
por: Urtishak, Karen A., et al.
Publicado: (2018)

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
por: Kim, Sang-Kyu, et al.
Publicado: (2018)

JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias
por: Delgado-Martin, C, et al.
Publicado: (2017)

Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children’s Oncology Group phase III study AALL0433
por: Lew, Glen, et al.
Publicado: (2020)

Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia
por: Ma, Xiaotu, et al.
Publicado: (2015)

THE GENOMIC LANDSCAPE OF PEDIATRIC AND YOUNG ADULT T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Liu, Yu, et al.
Publicado: (2017)

MLL Rearrangements Impact Outcome in HOXA-deregulated T-lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
por: Matlawska-Wasowska, Ksenia, et al.
Publicado: (2016)

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study
por: Maese, Luke, et al.
Publicado: (2023)

Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia
por: Reynolds, Christine, et al.
Publicado: (2014)

Germline Genetic Variation in ETV6 and Risk of Childhood Acute Lymphoblastic Leukemia: a Systematic Genetic Study
por: Moriyama, Takaya, et al.
Publicado: (2015)

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
por: Downes, Charlotte E. J., et al.
Publicado: (2021)

Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development
por: Roncero, A M, et al.
Publicado: (2016)

MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia
por: Evensen, Nikki A., et al.
Publicado: (2018)

Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-xL
por: Reeve, Janice LV, et al.
Publicado: (2007)

Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children
por: Xu, Heng, et al.
Publicado: (2015)

Aurora A kinase as a target for therapy in TCF3-HLF rearranged acute lymphoblastic leukemia
por: Leonard, Jessica, et al.
Publicado: (2021)

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
por: Flex, Elisabetta, et al.
Publicado: (2008)

Cost comparison by treatment arm and center‐level variations in cost and inpatient days on the phase III high‐risk B acute lymphoblastic leukemia trial AALL0232
por: DiNofia, Amanda M., et al.
Publicado: (2017)

Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia
por: Ryba, Tyrone, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_uakpk0shfl7pq3pj9eqv87vs2n